Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
- Citation:
- J Clin Oncol vol 26 (6) 848-55
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 803
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA03927, CA16450, CA31946, CA31983, CA33601, CA41287, CA45389, CA45418, CA47577, CA77658
- Corr. Author:
- Authors:
- Martin J Edelman Dee Watson Xiaofei Wang Carl Morrison Robert A Kratzke Scott Jewell Lydia Hodgson Ann M Mauer Ajeet Gajra Gregory A Masters Michelle Bedor Everett E Vokes Mark J Green
- Networks:
- Study
- CALGB-30203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carboplatin, Carcinoma, Non-Small-Cell Lung, Celecoxib, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Eicosanoids, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Hydroxyurea, Immunohistochemistry, Lipoxygenase Inhibitors, Logistic Models, Lung Neoplasms, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prognosis, Prospective Studies, Pyrazoles, Sulfonamides, Up-Regulation